Obinutuzumab Plus Chemotherapy Compared with Rituximab Plus Chemotherapy in Previously Untreated Italian Patients with Advanced Follicular Lymphoma at Intermediate–High Risk: A Cost-Effectiveness…

Overview of attention for article published in ClinicoEconomics and Outcomes Research: CEOR, July 2021

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 11 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 3,379 followers.

Obinutuzumab Plus Chemotherapy Compared with Rituximab Plus Chemotherapy in Previously Untreated Italian Patients with Advanced Follicular Lymphoma at Intermediate-High Risk: A Cost-Effectiveness Analysis #lymphoma #lymsm https://t.co/zVpAkzWhhZ

30 Jul 2021

Reply Repost Favourite

New article: Obinutuzumab Plus Chemotherapy Compared with Rituximab Plus Chemotherapy in Previously Untreated Italian Patients with Advanced Follicular Lymphoma at Intermediate-High Risk: A Cost-Effectiveness Analysis https://t.co/RpALhdJX5K #FL #lymsm #he

29 Jul 2021